Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Sanofi Synthelabo — Investor Presentation (February 2003)
85 slides from Sanofi Sa's investor presentation, Feb 19, 2003
Slide 1: Information Meeting February 2003
Information meeting — February 2008 - 4 Information Meeting February 2003 sanofi~synthelabo Because health matters
Slide 2: Forward-looking statements
iy, ill This release contains statements that constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or beliefs and are subject to a number of factors and uncertainties tha
Slide 3: Jean-François Dehecq, Chairman and CEO
Jean-Francois DEHECQ Chairman and Chief Executive Officer sanofi~synthelabo Information meeting — Februsry 2008 - 3 Ricsnenbealicendions.
Slide 4: 2002: Another year of strong sales growth
2002: Another year of strong sales growth One of the highest growth rates in the pharmaceutical industry = Consolidated sales 2002: +12.8% = Developed sales 2002: #14.5% Consolidated Developed sales sales Plavix®/ Iscover® +42% +32% Aprovel® / Avapro® | 434% | | +19% | Stilnox® / Ambien® Myslee® +26
Slide 5: 2002: Another year of strong growth in Net Profit
2002: Another year of strong growth in Net Profit* = Net Profit millions of euros ~ multiplied by 2.8 since 1999 — 24% of sales in 2002 +28% +43% anit > +54%, | <2 Ee 1999 2000 2004 2002 = EPS*: ineuros + 29% +44% — | on 3 cd 2000 2001 2002 * Betore exceptional tems andl doodwl amortisation sanofi~s
Slide 6: 2002: A successful year for new registrations
2002: A successful year for new registrations = Additional indications in the United States and in Europe —Plavix® in acute coronary syndrome ~ Aprovel®/Avapro® in diabetic nephropathy = Arixtra®: Registration and launch in the United States and in Europe = 3 registrations in the United States >Elox
Slide 7: 2002: Negative events
2002: Negative events = Plavix® patents challenged by two generic companies in the United States Reduction in US wholesale inventory of Plavix® and Avapro® Increased pressure on healthcare cost containment in Europe = Economic crisis in Latin America ssanofi~synthelabo WN) iweonnaion mecing = Februa
Slide 8: Stock Performance up to Feb. 2003
| Stock Performance up to Feb. 7 2003 Daily prices on base price of Dec. 30t 1999 CAE a) — Eure Stoxx 50 — STORE Pharma — Sanof-Syihélato . ee 400 a ioe Fah PP EPP PPPS GPP PPP SF O85 = EPS*: in euro 100 | i i 1999 2000 2001 2002 serra faites moar ernen sanori~synthelabo |) information meeting — Feb
Slide 9: Operations
Information meeting — February 2003 - 9 Operations Hanspeter SPEK Executive Vice President, Operations sanofi~synthelabo Because health matters
Slide 10: Double-digit growth worldwide
Double-digit growth worldwide = 2002 consolidated sales: EUR7,448 m (+12.8%) = 2002 developed sales: EUR 9,585 m (#14.5%) 2002 Consolidated sales Developed sales EURm Change EURm Change Europe 4,297 411.8% 4,372 +11.4% USA 1,689 #17.5% 3,504 ¥18.5% Other countries 1,462 +10.3% 1,709 +14.9% Total TA4
Slide 11: Sustained, superior growth in the USA
Sustained, superior growth in the USA = Demand growth: three times the market in 2002, after being two times in 2001 = Successful retake of Ambien®, combining — increased investment > accelerated growth = Healthy growth despite de-stocking > Plavix® = Prescriptions: + 35% = Developed sales: + 23% >
Slide 12: Increased presence in Europe
Increased presence in Europe Gaining market share in all markets except Italy Performance driven by top 1 products: +17% Very strong demand growth for Plavix®: +50%" = Irbesartan became # 2 in AIIRA market > NDA in diabetic nephropathy + 48 antihypertensive in France = NDA March 2002 and progressive
Slide 13: Solid performance in other countries
Solid performance in “other countries” = Continued growth in: > Australia +31% > Korea +63% > Algeria +14% > South Africa +20% = Good base established in China / Hong Kong / Taiwan + Sales ~EUR 100 m, +17% = Continued crisis in Latin America = Profit protection measures put in place = Demand growth
Slide 14: Presence and Future in Japan
Presence and Future in Japan = Strategy Monthly Market Share: Hypnoties (%) + Accelerate product development locally Myslee®: EUR 62m > Monitor and support existing partners’ activities 20% a > Continue to study opportunities for external growth + Prepare for direct presence = Growth drivers § + Mys
Slide 15: Stilnox/Ambien/Myslee performance and highlights
STILNOX®/AMBIEN®/MYSLEE Performance and highlights Sales in 2002 (Eur m) 1,455 1,424 +25% 43 +48% 66 +110% 139 -5% 8 Other counties © Japan Europe BUSA 1,208 +27% Consolidated Developed Changes on a comparable basis Source: IMS Health. All channels included = Continued high 2-digit growth: “Led by t
Slide 16: Ambien 2002 market performance
AMBIEN® 2002 Market performance = Ambien® continues to reinforce its robust position as the market leader = Clinically, Ambien® has become the “gold standard” = High brand loyalty with patients = New competitors expected to expand the market (as in the past) m= Ambie! is on track ife-cycle managemen
Slide 17: Zolpidem MR
ZOLPIDEM MR Warnox AMBIEN 3 = A patent, granted in the USA on February 4, 2003, protecting a specific dissolution profile ca] In vitro dissolution, Ne eas ena =. Li relative to Ambien’ Boe zopidem MR tablet i: dssoluion pri ne * invivacorretaton ai can be estabished Invivo : Ay absorption profile tn
Slide 18: Stilnox/Ambien/Myslee perspectives
STILNOX*/AMBIEN®/MYSLEE® E Perspectives \Brunox AMBIEN | ~ iy, = Fully leverage the untapped market potential in the USA and Japan = Further investment in the “as needed” mode of administration = Initiate further measures to build brand loyalty = Maintain pace on MR development and market preparatio
Slide 19: Plavix 2002
PLAVIX® 2002 Plavix Performance and highlights Sales 2002 (Eur m) 2,587 +32% Consolidated Developed B Non-UsA B usa IMSIGERS YTD 1122002 Changes on a comparable basis Performance continued at high level growth but burdened by de-stocking in the USA + USA 2002 TRx +35% vs 2001 CURE (ACS) > Rapid appr
Slide 20: Plavix: accelerating sales through CURE
PLAVIX® Accelerating sales through CURE Plavix —US- Tand Line USA Demand = Eurcpe -Dernand —urepe Trend Line Source: MS Heath /GERS Outstanding CURE results make Plavix® standard medication in acute coronary syndrome (ACS) FDAIEMEA approval of new indication (Feb. & Sep. 02) Rapid inclusion into AHA
Slide 21: Plavix: share of each indication
PLAVI Plavix | Share of each indication and growth rates _ IMS Demand sales #459 Top 5 countries (Eur m) % 2001 2002 i é [Cardiology = Neurology MPAD fi Others Source: IMS Top § countries in Eur m + Internal analysis sanofi~synthelabo , Girainnetne aca Sites tiiiceion
Slide 22: Plavix life cycle management
PLAVIX' Plavic Life Cycle Management = CREDO: ~ Results released on November 18 at the 2002 AHA Scientific Sessions = MATCH: > Secondary prevention after stroke o transient ischernic attack in high risk patients — clopidogrel + aspirin versus clopidogrel — recruitment completed (7,600 patients) = CO
Slide 23: Plavix: CREDO study
PLAVIX = CREDO study: long-term benefits of clopidogrel in PCI patients > Long-term results at 1 year demonstrate an overall 27% RRR (p=0.02) of the combined endpoint + Inthe ITT analysis, at 28 days, 19.7% RRR with pretreatment of clopidogrel 1 year results (MI, Stroke, or Death) Combined endpoint
Slide 24: Clopidogrel & Irbesartan ACTIVE trial design
PLAVIX® Plavi Clopidogrel & Irbesartan Al e Trossartan = ACTIVE Trial Design —— Patients with AF —q Warfarin not indicated Warfarin indicated * * ACTIVEA ACTIVE W + clopidogrel 75 + A + clopidogrel 75 + A vs. placebo + A vs. adjusted dose VKA + superiority trial + non-inferiority trial - double blin
Slide 25: Plavix perspectives
PLAVIX Perspectives = Multiple growth drivers in place: = Short-term = Increase penetration in CAPRIE, CURE and CREDO populations Increase treatment duration in the USA and in Europe Execute programs in medical education of the risk of atherothrombosis and peripheral arterial disease (PAD) Strengthe
Slide 26: Aprovel/Avapro 2002
APROVEL*/AVAPRO® 2002 Performance and highlights oesaran Sales 2002 (Eur m) Consolidated Developed BNon-US& ms YTD 112002 Changes on a comparable basis AIIRA class on the way to become the leading class in HTA (2002 growth: +28%) Irbesartan has become number 2 AIIRA in Europe with the strongest grow
Slide 27: Aprovel/Avapro market performance
APROVEL®/AVAPRO® Market performance APROVEL Tebesartan = Class value share in hypertension already up to 18.3% on a global basis = First or second rank for irbesartan achieved in most European markets following increase in SOV in 2002 = Significant wins in MCO accounts in the USA (+29% of covered li
Slide 28: Aprovel/Avapro life cycle management
APROVEL*/AVAPRO® Life Cycle Management Woesartan ZsEpre = ACTIVE ~ Prevention of stroke, MI, CV death in patients with atrial fibrillation — on top of either clopidogrel or warfarin — (10,000 patients) = |-Preserve ~ irbesartan in congestive heart failure with preserved systolic function - 1st patie
Slide 29: Aprovel/Avapro perspectives
APROVEL®/AVAPRO® RGR Perspectives veseartan = AIIRA will dominate the hypertension market and face no immediate competition = US market is gaining its usual worldwide share = AIIRA class is expanding beyond hypertension to diabetes and heart failure populations = Fully leverage USA potential for Ava
Slide 30: Arixtra market potential
ARIXTRA Market potential Global LMWH market in 2002 (Eur m) 1837 +19% 1,538 +£30% 1,02: 831 16% +18% 313 687 +24% +51% 8 ar ee 2001 mus m= Non-US ae = Low Molecular Weight Heparin market continues to exhibit strong growth 1472 = New market entrants must . wae overcome many hurdles 423%, eee ~ Spectr
Slide 31: Arixtra: where do we stand?
ARIXTRA® Where do we stand? Arixtré ospital formulary’ the USA and Europ 2002 Nb of hospital formulary = Growing access to the market 782 through formulary inclusion = 48% of US sales were generated in Q4 2002 = Gains in highly prestigious accounts in the USA = Growing recognition of advantages vers
Slide 32: Arixtra life cycle management
ARIXTRA® AriXtra | Life Cycle Management see = New labelling in the USA —-with an improved PI- in December 2002 = Long-term prevention in hip fracture — submitted in December 2002 = Curative treatment of Venous thrombo embolism — Submission in Q2 2003 = Ongoing development > Prevention of VTE in hig
Slide 33: Arixtra Matisse study designs
ARIXTRA® : Matisse Study Ariitra MATISSE study designs 25 days IV UFH (aPTT 1.5-2.5) + OAC (INR 2-3) 2.200 patients with PE + DVT Open-Label 25 days 7.5 mg fondaparinux” s¢ + OAC (INR 2-3) 2.200 patients with DVT Double-blind * 5 mgiif body-weight < 50 kg > 8 days SC enoxaparin (1 mgikg, bid) + OAC
Slide 34: Arixtra Matisse primary efficacy outcome
ARIXTRA® : Matisse Study AriXttra Primary Efficacy outcome (3 months) Fondaparinux(N=1103) UFH (N=1110) Fatal PE 16 (1.5%) 16 (1.4%) Non-fatal PE or DVT 26 (2.4%) 41 (3.6%) Matisse PE Total symptomatic recurrent VIE 42 (3.8%) 56 (5.0%) 3.0% 12% 0 05% A=3.5% « Fondaparinux - UFH (95% Cl) Fondaparinux
Slide 35: Arixtra Matisse principal safety outcome
ARIXTRA® Matisse Study er Principal Safety outcome Fondaparinux SEV 32% 4.5% Matisse PE UFH EEE 524 6.3% < Hi Major bleedings [J Clinically relevant non-major bleedings Fondaparinux REM OUZ6s0l 3.7% Matisse DVT LMWH MES NSO 4.2% i Major bleedings [Hl Clinically relevant non-major bleedings sanofi~sy
Slide 36: Arixtra perspectives
ARIXTRA® Ariktra Perspectives = Upcoming European launches open >65% of European prophylaxis market potential = Increased awareness of Precautionary Principle in context of synthetic origin = Life Cycle Management program on-track Tpaivation Eat Regatation | of LMWH market accessible® Major Orthoped
Slide 37: Xatral market situation and potential
XATRAL® Market situation and potential Global BPH market in September 2002 (Eur m) 2,548 983 975 a ae BE es USA Europe Japan World [ Consolidated sales 2002 (Eur m) | sales 2002 [ Consolidated sales 2002 (Eur m) | m) 182 2001 2002 Is ogr2002 Sales andl changes on a comparable basis Alpha-blockers ar
Slide 38: Eloxatin performance and highlights
ELOXATIN® Plexetior |= Performance and highlights = Coneol a = Demonstration of significant survival benefit in 1% line MCRC treatment over current US standard 389 +101% = Strong and continued growth USA outside USA 4 months = Launch in the USA, end August 2002 ~ Approval in 24 line MCRC 273 ~ Creat
Slide 39: Eloxatin market performance
E Market performance LOXATIN Bloxatin Us Eloxatin® and Camptosar® sales (in US$ m)* ad = Rapid adoption = More than 30% of Market share* versus Camptosar® by December 2002 and approximately 40% sare of patients starting treatment receiving Eloxatin® *DDD (IMS) OTN panel 3355 37 dtad 464s 48.14 Weeks
Slide 40: Eloxatin patents and submissions
ELOXATIN® = 3 patents listed in the Orange Book (high purity product by process) ~ Expiring in 2013 in Europe and USA = New patented formulation: ~ Patent expiration in 2015 ~ Submission planned Q1 2004 = Metastatic colorectal cancer in first-line ~ Submission planned in the USA Q3 2003 = Adjuvant t
Slide 41: Eloxatin ovarian cancer
ELOXATIN Ovarian Cancer = Study in Ovarian Cancer — preliminary results Overall Survival in the entire population : Leis 8 ~ Taxol + oxaliplatin in patients with advanced ovarian cancer pretreated with cisplatin or carboplatin Complete see response Partiel = response Response 84.5% TP “The median ov
Slide 42: Eloxatin perspectives
ELOXATIN® Perspectives = Market potential to triple by geographical expansion in the USA = Extensive life-cycle-management plan including more than 11.000 patients = Short Term 71% line treatment for MCRC in the USA — 24 jine treatment for MCRC in Europe = Mid Term > Adjuvant therapy > Radio-chemoth
Slide 43: Strategic products growing strongly for three consecutive years
| Strategic products growing strongly for three consecutive years 6 strategic products (Eur m) 6 Strategic Products account for: + 48% of consolidated sales versus 39% in 2001, growing +37% > 59% of developed sales versus 52% in 2001, growing +31% © Consolidated Sales © Developed Sales 4 i Plavix —_
Slide 44: Finance
Information meeting — February 2003 - 44 Finance Marie-Héléne LAIMAY Senior Vice President, Chief Financial Officer sanofi~synthelabo Because health matters
Slide 45: Strong Growth in Consolidated Sales
Strong Growth in Consolidated Sales Growth on a comparable basis: +12.8% 48.8% | = Impact of change in group structure: +4.5% ° = Currency impact: -2.5% + of which = US Dollar: -0.8% = Japanese Yen -0.5% 2000 2001 2002 ® Latin American currencies: -1.0% 8 In million euros Growth on a reported basis:
Slide 46: Gross Profit: Continuous growth and strong absolute ratio
Gross Profit: Continuous growth and strong absolute ratio = Positive drivers 2001 - 2002 +16% > Product mix improvement: +0.6% > Productivity improvement: +0.6% = Negative driver 2001 - 2002 + Plavix® and Avapro® destocking effect on royalty flow: -0.4% = Neutral item > Bulk sales of Ambien® offset
Slide 47: Operating Profit
Operating Profit = R&D Expenses: +18.1% (+20% at 2001 exchange rate) + 16.4% of sales > Strong increase due to on going Phase Ill clinical trials and Life Cycle Management > Agreements with IDM and Cephalon SG & A: 45.3% (+8% at 2001 exchange rate) ~ 32.6% of sales 7 Moderate increase versus 2001 af
Slide 48: Geographic breakdown of Operating Profit
| Geographic breakdown of Operating Profit* for 2002 = Strong growth in the USA in 2002: 1,781 Eur m, +36% US. 45% 522 Eur m, +14% Other countries 1,633 Eur m, +14% 4 Europe a 42% t 8 *3,936 million euros (Excluding non-allocated expenditure: 1.322 million euros) sanofi~synthelabo |) Information mee
Slide 49: Earnings Per Share: 2.42 euros, +29%
Earnings* Per Share: 2.42 euros, + 29% = Depreciation of intangibles: Net Profit’ in million euros 129 Eur m (vs.68 Eur m) > Ambien® and Avapro® in the USA +28% = Financial Income: 85 Eurm (vs.102 Eur m) > Mark to market adjustment of stock option plans: -46 Eur m “3% fe 961 4 + Impact of hedging po
Slide 50: Breakdown of growth factors of Net Profit
Breakdown of growth factors of Net Profit 1999/2000 = 2000/2001 += 2001/2002 Business Operations | +24% [| 434% | 424% Currency fluctuations +14% 42% 3% | Synergies [tom | em ___ Increase rights in Lorex JV 6% 2% 47% | © Net Profit growth | +54% || +43% || 428% A é sanofi~synthelabo Information meet
Slide 51: Cash Flow Statement
Cash Flow Statement = Operating Cash flow +30% > 2,260 Eur m vs. 1,732 Eur min 2001 = Change in need for working capital > 584 Eur m vs. -86 Eur m of which 413 Eur m corresponds to pending tax payments for 2001 and 2002 = Capital expenditures > 1,435 Eur m vs. 619 Eur min 2001 = Acquisition of 51% a
Slide 52: As of December 31st, 2002
8 As of December 31%, 2002 TotalFinaEif TotalFinaEit Public : sae 507% Employees| 19.5% Face Employees Treasury 14% Shares 42% sanofi~synthelabo Because health matters Information meating ~ February 2009-82
Slide 53: Share Buy Back Program
Share Buy Back Program = Treasury shares held in context of share buy back program = As of December 31%, 2002 = 164 million shares = 2.24% of Share Capital = 963 Eur m ~ As of February 17", 2003 = 21.5 million shares = 2.94% of Share Capital = 1,220 Eurm ssanofi~synthelabo WA), Wronmation meeting -
Slide 54: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account 2001 2002 var] Eurm | %CA | Eurm | %CA _ NET SALES 6488 100% | 7448) 100% | H1Sm Cost of goods sold (1.259 | 19%) || 7a | 19%) | +10% | GROSS PROFIT 3295| 81% | 6070| 81% | +eN R&D expenses (rast) | (16%) || (1.218 | (16%) | +16% Selling and general expenses (2.306
Slide 55: Consolidated Profit & Loss Account (ctd)
Consolidated Profit & Loss Account (ctd) 2001 2002 |[_var. | _eurm | ca | Eurm | % ca | PROFIT BEFORE TAX AND EXCEPTIONAL ITEMS 2140 | 33% 2,570 35% | 420% Exceptional items | 280 4% || io | 0% | -96% | income taxes (842) | (13%) (748) (10%) |) -12% Share in profits of equity associates 14 0% 20 0%
Slide 56: Cash flow statement table
2002 2001 Operating cash flaw 2,260 1,782 Change in need for warking capital (684) 86 CASH FLOW PROVIDED BY OPERATING ACTIVITIES Tes «818 Capital expenditures (1,438) (619) Proceeds from disposals 26 506 ‘CASH FLOW (USED IN)/PROVIDED BY INVESTING ACTIVITIES (1,409) (113) Capital increase and others
Slide 57: Simplified consolidated balance sheet
Simplified consolidated balance sheet 31/12/02 | 31/12/01 31/12/02 | 31/12/01 ‘ASSETS LIABILITIES AND SHAREHOLDERS’ EQUITY Fixed assets 2,899|/ 2,296 | Shareholders’ equity 6,035 5,768 Differed taxes 484 471 | Minority interests 7 24 Inventories, eat Icngrterm receivables and athers 2ga8|| 2,911 | l
Slide 58: Research & Development
Research & Development Gérard LE FUR Senior Executive Vice President Scientific Affairs sanofi~synthelabo Information meeting — February 2003 - $8 phi ds alia
Slide 59: R&D portfolio
R&D portfolio Phase lla Phase llb Phase Ill Cardiovascutar) ERENCE _ cardiovascular! TS aera srziaes | ‘ronetarone UREN ssrsszz00 | st csosr2 ” SSR 125047 auaa SSR 125543 oes Central Sohne | Sere | svereet eplivanserin | rimonabant Nervous SeRtHNETS | SSRANTEHT | Cl coiss | osanetant | Soipidemmn |
Slide 60: R&D portfolio changes
R&D portfolio changes = Development stopped for compounds in preclinical development and Phase | —~ SR 144190 (depression/anxiety) = SSR 69071 (COPD) > SL 25.1131 (smoking cessation) = Five new compounds entered preclinical development ~ SSR 97193, ferroquine (malaria) > SSR 241586, NK3/NK2 receptor
Slide 61: R&D portfolio changes
R&D portfolio changes = Four compounds in phase Il advanced into the following phase: ~ idraparinux, once a week anti Xa, entered Phase III (thrombosis) 7 SR 31747, peripheral sigma ligand, entered Phase IIb (oncology) ~ saredutant, NK2 antagonist, entered Phase IIb (IBS) ~ SR 121463, vasopressin V,
Slide 62: Cardiovascular/Thrombosis
Cardiovascular/Thrombosis Arixtr: fondaparinux prevention of thrambo-embalic events ‘ler major orthopedic surgery) Approved! Launched ‘LCM ‘Aprovel® irbesartan {ciabetic nephropathy, CHF) Plavix® clopidogrel {unstable angina, prevention in at risk patients) Submitted fondaparinux SR 90107, pentasacc
Slide 63: idraparinux SanOrg34006
idraparinux SanOrg34006 = Once a week synthetic anti Xa oligosaccharide = Treatment and secondary prophylaxis of venous thrombo-embolic events in patients with deep venous thrombosis or pulmonary embolism = Prevention of thrombo-embolic events associated with atrial fibrillation = Entered phase III
Slide 64: idraparinux Phase III program
idraparinux SanOrg34006 Phase III program = Venous Thrombo embolism (Van Gogh program) = two studies : . deep vein thrombosis : 2,200 patients . pulmonary embolism : 2,200 patients idraparinux versus vitamin K antagonist - 3/6-month treatment duration ~ followed by one extension study : (n > 1,200 p
Slide 65: dronedarone SR 33589
dronedarone SR 33589 = Phase Ill program in atrial fibrillation -ANDROMEDA - morbi-mortality study in high risk patients with CHF- discontinued following DSMB recommendation on January, 17th 2003 72 pivotal trials: maintenance of sinus rhythm in patients with atrial fibrillation = EURIDIS (Europe) —
Slide 66: SR 121463 Aquaretic
SR 121463 Aquaretic = Phase Ilb = Selective vasopressin V, receptor antagonist = Pure aquaretic compound, orally-active = Development is ongoing in the following indications: ~ Treatment of SIADH* — Symptomatic treatment of CHF ~ Acute treatment and prevention of relaps in patients with cirrhotic as
Slide 67: SR 121463 Aquaretic repeated dose study
SR 121463 Aquaretic = Repeated oral ascending dose study in volunteers ~ Mean urinary flow rate (mLimin) versus time Ew 4 a = 8 ee —*— placebo Bs 7 E —— 1mg 0D a ot Time (hours) 10 mg OD & —— 25mg OD en F Ea —+— 50mg oD £, —*— 100 mg OD i es 2 Bea = 5 é ot Time hours) 102093 4 6 6 7 8 sanofi~synthel
Slide 68: Oncology
Oncology i i ELOXATING oxaliplatin [volaracta canoer) FASTURTEC® /ELITEK® rasburicase (chemetherapy-associatedhyparuiceria) Submitted Phase Ill oxaliplatin sro (evarin canoer, sdjwanttreatment) tirapazam SR 269075 {non-small call lung cancer, head & nack cancer) e Phase lib SR 31747 periph. sigmalig
Slide 69: Nervous System
Nervous System JW YSLEE® zolpidem {insomnia} STICNOX@AMETENS Zolpidem MR Timonabart Noid Release SRIAITIE/OET antag, ‘inom Timing cet ton) SR 5a peory eplivanserin ‘oeanetant 8 aporist GABAA agonist ‘raged, 5HT2 antag, SR 12E01, Ne antag, (apretaon) lomtetamuei coset) ‘ies ahordsre Toenzopreay ‘ered
Slide 70: Osanetant SR 142801
Osanetant SR 142801 = Phase Ilb in major depressive disorders (outpatients) 3 fixed doses of SR142801 versus placebo and paroxetine 6-week, randomized, double-blind, controlled trial Percent of patients whe responded 0% (treatment —fast visi) Mean change from baseline HAM-D total score ens qT) (BP a
Slide 71: SR 58611 Depression
SR 58611 Depression = Phase lla study > Inpatients with recurrent major depression and melancholia HAM-D 17 - Mean Change (95% Cl) from baseline o-. £0 2 2 Zu 3 P=0.0031 4 3° Bas 2 a Visit Day 2 7 4 a 2 2 2 g 2 - Fluoxetine (29 maid) SR 56511 (600 mat) i n=15 nat? sanofi~synthelabo WA), tonnation me
Slide 72: SR 58611 Depression
SR 58611 Depression = Phase lb in and outpatients with recurrent major depression and melancholia Main Efficacy Criterion HAM-D 17 ITT’ Population et) os. et 63.7% 70% ot 1% coe a at 20% 0% ae on 20% sos 18% 20% 10% Percent of patients who Percent of patients with HAM-D responded HAMD total score to
Slide 73: SR 58611 Depression
SR 58611 Depression = Phase IIb Main Efficacy Criterion HAM-D 17 PP* Population aos os o58 en 208 208 18% 0% Percent of patients who HAMLDtotal score Percent of patients with HAM-D responded Mean change from baseli total score <8 at week 6 ‘ a 0 Di Paroxetine (20 mg) o 84 (roe 12 a DSR 58611 (300 mg
Slide 74: SR 58611 Depression safety results
SR 58611 Depression = = Phase IIb Paroxetine SROGOTT 20 mg (n=65) [300 ma (n=64) | 600 Overview of safety results Number (") 25 29 a Patients with any TEAE (including SAEs) ee ia eer Treatment emergent adverse events‘ Any event 385 45.3 38 Central and peripheral nervous system: 20.0 188 136 - dizzin
Slide 75: SR 58611 PET Scan Depression
| SR 58611 — PET Scan Depression $R58611 increases acti Mood Disorders in the same area “.., an area of abnormally decreased activity in the prefrontal cortex ventral to the genu of the corpus callosum in both familial bipolar depressives and familial unipolar depressives has been localized.” asR 58
Slide 76: Internal Medicine
Internal Medicine XATRAL OD. @ situzosin yas (BPH? EUR) XATRAL OD. sifusosin (BPH US) alfuzosi nonabant fumagitl oii ct anteg SR 181716, C81 antag, SR ota {acute urinary retention) (obesity) (irtestinal mirozperiiosis) ‘saredutant ora SR aBGCEnNK2 antag, fi) ‘SR 48692 'SR 140333, mae ne neurotensin,
Slide 77: rimonabant Phase III smoking cessation
rimonabant SR 141716 = Phase Ill program in Smoking Cessation Placebo/5 mg / 20mg EFC4964 US 10-week treatment ErcaaTa BU N= 780 patients {for each study) Placebo! 5 mg/20 mg EFC4796 USI Canada’ 12-month treatment Australia N= 4,000 patients Aid to Smoking Cessation ssanofi~synthelabo intonation mee
Slide 78: rimonabant Phase III obesity
rimonabant SR 141716 = Ongoing Phase III program in Obesity 76,180 obese patients —5 mg and 20 mg versus placebo RIO-North America: 2,800 patients, recruitment completed, 2 years duration RIO-Europe: 1,400 patients, recruitment completed, 2 years duration RIO-Lipids: 990 patients, recruitment comple
Slide 79: Registration Status
Registration Status = Aprovel®/Avapro® in type 2 diabetic nephropathy US: Approved on September 18, 2002 Japan: Hypertension submitted on October 31, 2002 = Plavix® in acute coronary syndrome with non-ST segment elevation Europe: Approved on September 20, 2002 = Arixtra® in long-term prevention of V
Slide 80: R&D Portfolio
R&D Portfolio = 52 compounds under development Pre- clinica Phase! Phase lla Phase lib Phase lll Tota! Cardiovascular Thrombosis 3 q ° 1 | 2 9 Central Nervous System | 7 é 2 | 6 | 2 | 20 ‘Oncology | 1 | 2 2 1 | 1 | 7 Internal Medicine 6 | 4 2 1 | te « | 9 1 | = 23 compounds in phases II and Ill = 29
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Signatures
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: February 19, 2003 SANOFI-SYNTHELABO By: /s/ Marie-Helene Laimay Name: Marie-Helene Laimay Title:
Sanofi Synthelabo — Investor Presentation (February 2003) on 6ix